EDGAR Filing Documents for 0001640334-20-002108

Form 424B5 - Prospectus [Rule 424(b)(5)]:

SEC Accession No. 0001640334-20-002108

Filing Date

2020-08-14

Accepted

2020-08-14 06:02:23

Documents

Document Format Files

Seq	Description	Document	Type	Size
1	424B5	nymox_424b5.htm	424B5	320349
2		nymox_424b5img1.jpg	GRAPHIC	2916
3		nymox_424b5img2.jpg	GRAPHIC	2916
4		nymox_424b5img3.jpg	GRAPHIC	2916
	Complete submission text file	0001640334-20-002108.txt		333797

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-237564 | Film No.: 201101136
SIC: 2835 In Vitro & In Vivo Diagnostic Substances